Is MOTS-c Legal in North Carolina? What Women Need to Know

What Is MOTS-c and Why Are Women Asking About It

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome, specifically from the 12S rRNA gene. It regulates glucose metabolism, improves insulin sensitivity, and appears to reduce fat accumulation in animal models. Researchers first characterized it in a 2015 Cell paper by Lee and colleagues, which showed that MOTS-c injected into mice improved insulin resistance and reduced diet-induced obesity.

That single paper started a wave of interest.

Women are paying attention for reasons that map directly onto female physiology. PCOS affects roughly 8 to 13 percent of women of reproductive age worldwide, and insulin resistance sits at the center of that condition. Perimenopause brings a well-documented shift toward visceral fat accumulation and declining insulin sensitivity, independent of calorie intake. MOTS-c's proposed mechanism, activating the AMPK pathway and folate cycle in skeletal muscle, looks theoretically attractive for both populations.

That theoretical attractiveness is exactly why it matters to be clear-eyed about what is proven versus what is extrapolated.

What the Research Actually Shows So Far

The human data on MOTS-c is thin. A small 2021 study published in PNAS found that circulating MOTS-c levels in humans decline with age and are lower in older adults with type 2 diabetes. Exogenous MOTS-c improved insulin sensitivity in a rodent model in that same paper, but no randomized controlled trial in humans has been completed and published as of this article's review date.

No Phase 2 or Phase 3 clinical trial data in women are available. The evidence gap here is real, and it reflects a broader pattern: women are routinely underrepresented in metabolic peptide research. What you read on wellness forums is almost entirely extrapolated from mouse studies and theoretical mechanism.

The Mitochondrial Angle and Women's Health

Mitochondrial function changes across the female lifespan. Estrogen has direct mitochondrial effects, and the withdrawal of estrogen during perimenopause is associated with reduced mitochondrial biogenesis and increased oxidative stress. MOTS-c's mitochondrial origin makes it biologically plausible as a target for research in perimenopausal women. Plausible is not proven. No trial has tested MOTS-c specifically in perimenopausal women.

The Federal Legal Framework: Where MOTS-c Actually Stands

This is the section that matters most if you are trying to get MOTS-c in North Carolina right now.

FDA Approval Status

MOTS-c has no FDA approval as a drug product. That means no pharmaceutical company has completed the New Drug Application process, and no labeled indication, dose, or safety profile has been reviewed and cleared by the agency. It is not on the FDA's approved drug list.

The Bulk Substances List and Compounding

The main legal pathway for unapproved peptides in the United States runs through compounding pharmacies operating under Section 503A or Section 503B of the Federal Food, Drug, and Cosmetic Act.

503A pharmacies compound for individual patients based on a valid prescription from a licensed practitioner. 503B outsourcing facilities produce larger batches for distribution to healthcare facilities.

The FDA maintains what is informally called the "bulk substances" list, a list of substances that compounding pharmacies may or may not use. MOTS-c was nominated for evaluation on the 503A Bulks List, which means the FDA is actively reviewing whether pharmacies can legally compound it. As of this article's review date, MOTS-c has not been placed on the positive list of substances that are clearly permitted. Its status sits in the review category, which creates genuine legal uncertainty.

Compounding a substance that is under review or has been denied placement on the 503A positive list carries regulatory risk for the pharmacy. This affects whether any given North Carolina compounding pharmacy will agree to fill a prescription for MOTS-c.

Research Use vs. Clinical Use

Some vendors sell MOTS-c labeled "for research use only." These products are not regulated as drugs, are not compounded under pharmacy board oversight, and carry no quality assurance for human administration. Purchasing this type of product and self-injecting it is not a legal medical treatment pathway. It is also genuinely dangerous: purity, sterility, and actual peptide content are not verified by any regulatory body.

North Carolina State Law: What Applies and What Does Not

North Carolina does not have a statute that names MOTS-c or bans it by name. That is not the same as MOTS-c being clearly legal to prescribe and dispense in the state.

The North Carolina Medical Practice Act

The North Carolina Medical Board regulates physician practice under North Carolina General Statute Chapter 90, Article 1. Prescribing a substance with no established evidence base, no FDA approval, and no recognized standard of care is not automatically prohibited, but it does expose a prescriber to scrutiny under the standard of care framework. Any North Carolina physician, NP, or PA who prescribes MOTS-c must be able to document clinical rationale. The board has authority to investigate prescribing practices that fall outside accepted medical standards.

The North Carolina Board of Pharmacy

The North Carolina Board of Pharmacy governs compounding pharmacies in the state. State compounding rules operate alongside, not instead of, federal FDA rules. A North Carolina compounding pharmacy must follow both state board requirements and federal 503A/503B regulations. If the FDA concludes MOTS-c cannot be used in 503A compounding, North Carolina pharmacies cannot compound it regardless of any state rule or lack thereof.

What This Means Practically

There is no North Carolina law that explicitly permits MOTS-c either. The state framework is silent on this specific peptide. That silence means:

• A licensed North Carolina provider may write a prescription, and doing so is not automatically illegal under state law.
• A North Carolina 503A compounding pharmacy may fill that prescription, subject to FDA bulk substances rules.
• The federal regulatory uncertainty around MOTS-c compounding means any pharmacy that fills the prescription is taking on regulatory risk.
• The legal situation can change without notice if the FDA makes a final determination.

Think of this as a three-layer check: federal FDA status (unsettled), state pharmacy board compliance (follows federal floor), and prescriber standard of care (documented clinical rationale required). All three must align for a legal dispensing to occur in North Carolina.

How to Get MOTS-c in North Carolina Through a Legal Pathway

Getting MOTS-c through a legitimate medical channel in North Carolina requires several steps, none of which can be skipped.

Step 1: Find a Licensed North Carolina Provider

You need a prescription from a provider licensed in North Carolina. That means a physician (MD or DO), a nurse practitioner with prescriptive authority, or a physician assistant working under the appropriate scope. The provider should have documented familiarity with peptide therapies and be able to articulate why MOTS-c is being considered for your specific clinical picture.

Telehealth is legal in North Carolina for established prescriber-patient relationships. A telehealth provider must be licensed in North Carolina to prescribe to you as a North Carolina resident.

Step 2: Understand What a Legitimate Consultation Looks Like

A provider who prescribes MOTS-c without any clinical workup is a red flag. A reasonable consultation for a woman seeking MOTS-c for metabolic health should include:

• Fasting insulin, HOMA-IR, or glucose tolerance data
• Lipid panel and inflammatory markers
• Thyroid function (TSH, free T4 at minimum), because hypothyroidism mimics and compounds insulin resistance
• Menstrual history and reproductive stage assessment
• Discussion of established, evidence-backed interventions already tried or in progress

Step 3: Identify a Compliant Compounding Pharmacy

Not all compounding pharmacies in North Carolina currently compound MOTS-c. Given the FDA bulk list uncertainty, some pharmacies have chosen not to take on the regulatory risk. Your prescribing provider should work with a PCAB-accredited or state-licensed 503A compounding pharmacy that can document its sourcing, sterility testing, and beyond-use dating practices. Ask for a Certificate of Analysis for any compounded peptide product.

Step 4: Know That Pricing and Supply Are Unstable

Because MOTS-c is not FDA-approved and supply depends on compounding pharmacies, pricing is not standardized and can shift significantly if the FDA's bulk substances determination changes. Costs for compounded MOTS-c have ranged from roughly $150 to $400 per month at the time of research, but this should not be taken as a price guarantee.

Pregnancy, Lactation, and Contraception: Required Information

If you are pregnant, trying to conceive, or breastfeeding, do not use MOTS-c.

No human pregnancy safety data exist. No lactation transfer studies exist. MOTS-c has not been assigned an FDA pregnancy category under the legacy system, and it has not received a label under the newer Pregnancy and Lactation Labeling Rule because it has never received FDA approval at all.

Animal reproduction studies are limited. The 2015 Lee et al. Study showed metabolic effects in mice but did not assess reproductive toxicity, embryo development, or fetal outcomes in any detail.

Why This Matters by Life Stage

Reproductive years (actively cycling, not trying to conceive): If you are sexually active and could become pregnant, reliable contraception is a prerequisite before starting any unapproved peptide. Discuss your contraceptive plan with your provider before the first dose.

Trying to conceive: Avoid MOTS-c entirely. No safety data, and the AMPK-activating mechanism of this peptide could theoretically interfere with early implantation or embryo development, though this has not been directly studied. The absence of data is not reassurance.

Pregnancy: Contraindicated based on absence of safety data. Any effect on mitochondrial function during organogenesis carries theoretical risk that cannot be characterized without human data.

Postpartum and lactation: Avoid. Transfer into breast milk has not been studied. Peptide fragments could potentially reach a nursing infant.

Perimenopause: This is the population with the most theoretical interest in MOTS-c given metabolic changes tied to estrogen withdrawal. Women in perimenopause are often not actively using contraception, but irregular cycles mean pregnancy is still possible until 12 months after the final menstrual period. Pregnancy status should be confirmed before starting any unapproved peptide in the late perimenopause transition.

Post-menopause: If confirmed post-menopausal (12 months without a period, or documented FSH elevation), pregnancy risk is effectively zero. This is the group in which theoretical metabolic benefits could be evaluated with the least reproductive-safety complexity, though human trial data are still absent.

Who This May Be Right For, and Who Should Not Use It

This is not a checklist for self-prescribing. It is a clinical framing for conversations with your provider.

Women for Whom a Conversation with a Provider Makes Sense

• Post-menopausal women with documented insulin resistance who have tried lifestyle intervention and metformin and are still seeking adjunct strategies, and who understand they are working outside established evidence
• Perimenopausal women with PCOS and persistently elevated fasting insulin, not pregnant or trying to conceive, who want to discuss emerging mitochondrial-targeted approaches under close monitoring
• Women in a clinical research context, where MOTS-c might be available through a formal trial

Women Who Should Not Use MOTS-c at This Time

• Anyone pregnant, trying to conceive, or breastfeeding (see above)
• Women with active cancer or a history of hormone-sensitive cancer, given the absence of oncology safety data
• Women taking medications that significantly affect the AMPK pathway, such as metformin or berberine, without explicit provider oversight of potential additive effects
• Women who are relying on "research use only" unregulated product sources

What Women With PCOS Should Know Specifically

PCOS affects approximately 1 in 10 women of reproductive age according to ACOG. Insulin resistance is present in roughly 70 percent of women with PCOS, even those with a normal body mass index. The AMPK pathway that MOTS-c activates is the same pathway targeted by metformin, which has decades of safety data in PCOS and a well-documented effect on menstrual regularity, ovulation, and metabolic markers.

Metformin is the evidence-backed first choice for insulin-resistant PCOS. Any discussion of MOTS-c in PCOS should begin with an honest accounting of whether metformin, inositol supplementation, and lifestyle modification have been adequately tried first. The Endocrine Society's 2023 clinical practice guideline on PCOS does not mention MOTS-c because no human evidence supports its use in this population yet.

Women with PCOS who are trying to conceive face a particular problem: they are both the population with potentially the most metabolic reason to consider MOTS-c and the population for whom MOTS-c is explicitly off the table due to absent pregnancy safety data.

Monitoring If You and Your Provider Decide to Proceed

If you are a confirmed non-pregnant adult woman in North Carolina, working with a licensed prescriber, and using MOTS-c from a properly documented compounding pharmacy, the following monitoring framework reflects what a conservative clinical approach looks like.

Baseline labs before starting should include fasting glucose, fasting insulin, hemoglobin A1c, a complete metabolic panel, CBC, and thyroid function. Lipid panel and CRP add useful context.

Repeat metabolic labs at 8 to 12 weeks. Any unexpected changes in liver enzymes, kidney function, or complete blood count should prompt an immediate hold and provider review.

Your provider should document clinical rationale in your chart, including your informed consent to treatment with an unapproved compound with limited human evidence.

Frequently Asked Questions